Ernexa Therapeutics Inc. Direct Operating Costs
Ernexa Therapeutics Inc. (ERNA) reported Direct Operating Costs of $613.00 thousand for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DirectOperatingCosts · last filed 2020-08-07
- Ernexa Therapeutics Inc. direct operating costs for the quarter ending 2020-06-30 was $613.00K, a 64.30% decline year-over-year.
- Ernexa Therapeutics Inc. direct operating costs for the quarter ending 2020-03-31 was $950.00K, a 35.98% decline year-over-year.
- Ernexa Therapeutics Inc. direct operating costs for the quarter ending 2019-12-31 was $2.94M, a 43.25% increase year-over-year.
- Ernexa Therapeutics Inc. direct operating costs for the quarter ending 2019-09-30 was $1.34M, a 36.45% decline year-over-year.
- Ernexa Therapeutics Inc. direct operating costs for fiscal 2019 was $7.48M, a 7.27% decline from fiscal 2018.
- Ernexa Therapeutics Inc. direct operating costs for fiscal 2018 was $8.07M, a 19.47% increase from fiscal 2017.
- Ernexa Therapeutics Inc. direct operating costs for fiscal 2017 was $6.75M, a 12.39% decline from fiscal 2016.
- Ernexa Therapeutics Inc. direct operating costs for fiscal 2016 was $7.71M, a 38.66% decline from fiscal 2015.
| Period end | Direct Operating Costs 3 month | Direct Operating Costs 6 month | Direct Operating Costs 9 month | Direct Operating Costs 12 month |
|---|---|---|---|---|
| 2020-06-30 | $613.00K 10-Q · filed 2020-08-07 | $1.56M 10-Q · filed 2020-08-07 | $4.50M derived: sum of 3 quarters · filed 2020-08-07 | $5.84M derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | $950.00K 10-Q · filed 2020-05-20 | $3.89M derived: sum of 2 quarters · filed 2020-05-20 | $5.23M derived: sum of 3 quarters · filed 2020-05-20 | $6.95M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $4.28M derived: sum of 2 quarters · filed 2020-03-19 | $6.00M derived: sum of 3 quarters · filed 2020-08-07 | $7.48M 10-K · filed 2020-03-19 |
| 2019-09-30 | $1.34M 10-Q · filed 2019-11-01 | $3.06M derived: sum of 2 quarters · filed 2020-08-07 | $4.54M 10-Q · filed 2019-11-01 | $6.60M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-06-30 | $1.72M 10-Q · filed 2020-08-07 | $3.20M 10-Q · filed 2020-08-07 | $5.25M derived: sum of 3 quarters · filed 2020-08-07 | $7.37M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $1.48M 10-Q · filed 2020-05-20 | $3.54M derived: sum of 2 quarters · filed 2020-05-20 | $5.65M derived: sum of 3 quarters · filed 2020-05-20 | $7.59M derived: sum of 4 quarters · filed 2020-05-20 |
| 2018-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $4.17M derived: sum of 2 quarters · filed 2020-03-19 | $6.10M derived: sum of 3 quarters · filed 2020-03-19 | $8.07M 10-K · filed 2020-03-19 |
| 2018-09-30 | $2.12M 10-Q · filed 2019-11-01 | $4.05M derived: sum of 2 quarters · filed 2019-11-01 | $6.02M 10-Q · filed 2019-11-01 | $7.76M derived: sum of 4 quarters · filed 2019-11-01 |
| 2018-06-30 | $1.94M 10-Q · filed 2019-08-12 | $3.90M 10-Q · filed 2019-08-12 | $5.65M derived: sum of 3 quarters · filed 2019-08-12 | $7.18M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $1.97M 10-Q · filed 2019-05-14 | $3.71M derived: sum of 2 quarters · filed 2019-05-14 | $5.25M derived: sum of 3 quarters · filed 2019-05-14 | $6.88M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $3.28M derived: sum of 2 quarters · filed 2019-03-22 | $4.91M derived: sum of 3 quarters · filed 2019-03-22 | $6.75M 10-K · filed 2019-03-22 |
| 2017-09-30 | $1.54M 10-Q · filed 2018-11-09 | $3.17M derived: sum of 2 quarters · filed 2018-11-09 | $5.01M 10-Q · filed 2018-11-09 | $7.10M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $1.63M 10-Q · filed 2018-08-06 | $3.47M 10-Q · filed 2018-08-06 | $5.56M derived: sum of 3 quarters · filed 2018-08-06 | $7.31M derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-03-31 | $1.84M 10-Q · filed 2018-05-11 | $3.93M derived: sum of 2 quarters · filed 2018-05-11 | $5.68M derived: sum of 3 quarters · filed 2018-05-11 | $7.52M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $3.83M derived: sum of 2 quarters · filed 2018-03-09 | $5.67M derived: sum of 3 quarters · filed 2018-03-09 | $7.71M 10-K · filed 2018-03-09 |
| 2016-09-30 | $1.75M 10-Q · filed 2017-11-08 | $3.59M derived: sum of 2 quarters · filed 2017-11-08 | $5.62M 10-Q · filed 2017-11-08 | $8.97M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $1.84M 10-Q · filed 2017-08-04 | $3.88M 10-Q · filed 2017-08-04 | $7.22M derived: sum of 3 quarters · filed 2017-08-04 | $10.42M derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | $2.04M 10-Q · filed 2017-05-04 | $5.38M derived: sum of 2 quarters · filed 2017-05-04 | $8.58M derived: sum of 3 quarters · filed 2017-05-04 | $11.96M derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $6.54M derived: sum of 2 quarters · filed 2017-03-09 | $9.92M derived: sum of 3 quarters · filed 2017-03-09 | $12.57M 10-K · filed 2017-03-09 |
| 2015-09-30 | $3.20M 10-Q · filed 2016-11-09 | $6.58M derived: sum of 2 quarters · filed 2016-11-09 | $9.22M 10-Q · filed 2016-11-09 | $12.78M derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | $3.38M 10-Q · filed 2016-08-04 | $6.03M 10-Q · filed 2016-08-04 | $9.58M derived: sum of 3 quarters · filed 2016-08-04 | $11.84M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | $2.65M 10-Q · filed 2016-05-09 | $6.21M derived: sum of 2 quarters · filed 2016-05-09 | $8.46M derived: sum of 3 quarters · filed 2016-05-09 | $11.27M derived: sum of 4 quarters · filed 2016-05-09 |
| 2014-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $5.81M derived: sum of 2 quarters · filed 2016-03-15 | $8.62M derived: sum of 3 quarters · filed 2016-03-15 | $11.15M 10-K · filed 2016-03-15 |
| 2014-09-30 | $2.26M 10-Q · filed 2015-11-09 | $5.06M derived: sum of 2 quarters · filed 2015-11-09 | $7.59M 10-Q · filed 2015-11-09 | $10.26M derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-06-30 | $2.81M 10-Q · filed 2015-08-10 | $5.34M 10-Q · filed 2015-08-10 | $8.01M derived: sum of 3 quarters · filed 2015-08-10 | $9.54M derived: sum of 4 quarters · filed 2015-08-10 |
| 2014-03-31 | $2.53M 10-Q · filed 2015-05-08 | $5.20M derived: sum of 2 quarters · filed 2015-05-08 | $6.73M derived: sum of 3 quarters · filed 2015-05-08 | $8.22M derived: sum of 4 quarters · filed 2015-05-08 |
| 2013-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $4.20M derived: sum of 2 quarters · filed 2015-03-27 | $5.69M derived: sum of 3 quarters · filed 2015-03-27 | $7.69M 10-K · filed 2015-03-27 |
| 2013-09-30 | $1.53M 10-Q · filed 2014-11-07 | $3.02M derived: sum of 2 quarters · filed 2014-11-07 | $5.02M 10-Q · filed 2014-11-07 | $6.48M derived: sum of 4 quarters · filed 2014-11-07 |
| 2013-06-30 | $1.49M 10-Q · filed 2014-08-14 | $3.48M 10-Q · filed 2014-08-14 | $4.95M derived: sum of 3 quarters · filed 2014-08-14 | $6.47M derived: sum of 4 quarters · filed 2014-08-14 |
| 2013-03-31 | $2.00M 10-Q · filed 2014-05-15 | $3.47M derived: sum of 2 quarters · filed 2014-05-15 | $4.99M derived: sum of 3 quarters · filed 2014-05-15 | $6.54M derived: sum of 4 quarters · filed 2014-05-15 |
| 2012-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $2.99M derived: sum of 2 quarters · filed 2014-03-31 | $4.54M derived: sum of 3 quarters · filed 2014-03-31 | $6.16M 10-K · filed 2014-03-31 |
| 2012-09-30 | $1.52M 10-Q · filed 2013-11-14 | $3.07M derived: sum of 2 quarters · filed 2013-11-14 | $4.69M 10-Q · filed 2013-11-14 | $6.25M derived: sum of 4 quarters · filed 2013-11-14 |
| 2012-06-30 | $1.55M 10-Q · filed 2013-08-14 | $3.17M 10-Q · filed 2013-08-14 | $4.73M derived: sum of 3 quarters · filed 2013-08-14 | $6.05M derived: sum of 4 quarters · filed 2013-08-14 |
| 2012-03-31 | $1.62M 10-Q · filed 2013-05-13 | $3.18M derived: sum of 2 quarters · filed 2013-05-13 | $4.49M derived: sum of 3 quarters · filed 2013-05-13 | $5.90M derived: sum of 4 quarters · filed 2013-05-13 |
| 2011-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $2.88M derived: sum of 2 quarters · filed 2013-03-29 | $4.28M derived: sum of 3 quarters · filed 2013-03-29 | $5.81M 10-K · filed 2013-03-29 |
| 2011-09-30 | $1.31M 10-Q · filed 2012-11-09 | $2.72M derived: sum of 2 quarters · filed 2012-11-09 | $4.24M 10-Q · filed 2012-11-09 | $5.72M derived: sum of 4 quarters · filed 2012-11-09 |
| 2011-06-30 | $1.41M 10-Q · filed 2012-08-14 | $2.93M 10-Q · filed 2012-08-14 | $4.41M derived: sum of 3 quarters · filed 2012-08-14 | $5.93M derived: sum of 4 quarters · filed 2012-08-14 |
| 2011-03-31 | $1.52M 10-Q · filed 2012-05-11 | $3.00M derived: sum of 2 quarters · filed 2012-05-11 | $4.52M derived: sum of 3 quarters · filed 2012-05-11 | $6.05M derived: sum of 4 quarters · filed 2012-05-11 |
| 2010-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $3.00M derived: sum of 2 quarters · filed 2012-03-30 | $4.52M derived: sum of 3 quarters · filed 2012-03-30 | $6.06M 10-K · filed 2012-03-30 |
| 2010-09-30 | $1.52M 10-Q · filed 2011-11-14 | $3.05M derived: sum of 2 quarters · filed 2011-11-14 | $4.59M 10-Q · filed 2011-11-14 | |
| 2010-06-30 | $1.53M 10-Q · filed 2011-08-12 | $3.07M 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |